Day One Biopharmaceuticals, Inc.

How big is Day One Biopharmaceuticals, Inc.?

As of Jun 18, Day One Biopharmaceuticals, Inc. has a market capitalization of 658.86 million and reported net sales of 161.92 million with a net loss of 69.08 million. Shareholder's funds are 502.75 million, and total assets amount to 582.79 million.

As of Jun 18, Day One Biopharmaceuticals, Inc. has a market capitalization of 658.86 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the company reported net sales of 161.92 million for the latest four quarters. During the same period, the net profit was recorded at -69.08 million, indicating a loss.<BR><BR>As of Dec 24, the reporting period shows shareholder's funds amounting to 502.75 million and total assets of 582.79 million.

What does Day One Biopharmaceuticals, Inc. do?

Day One Biopharmaceuticals, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, reporting net sales of $31 million and a net loss of $36 million as of March 2025. The company has a market cap of $658.86 million and does not pay dividends.

Overview:<BR>Day One Biopharmaceuticals, Inc. operates in the Pharmaceuticals & Biotechnology industry and is categorized as a micro-cap company.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 31 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -36 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 658.86 Million (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.99 <BR>Return on Equity: -14.41% <BR>Price to Book: 1.37<BR><BR>Contact Details:<BR>Registrar Address: Not available.

Should I buy, sell or hold Day One Biopharmaceuticals, Inc.?

Is Day One Biopharmaceuticals, Inc. overvalued or undervalued?

As of July 30, 2024, Day One Biopharmaceuticals, Inc. is considered risky and overvalued due to significant negative financial metrics and a year-to-date return of -43.09%, underperforming the S&P 500's 12.22%.

As of 30 July 2024, the valuation grade for Day One Biopharmaceuticals, Inc. has moved from does not qualify to risky, indicating increased concerns regarding its financial health. The company appears to be overvalued given its significant negative metrics, including a Price to Book Value of 1.52, an EV to Sales ratio of 1.58, and an alarming ROCE of -2922.95%. In comparison, SAGE Therapeutics, Inc., a peer in the same industry, has a more favorable EV to EBITDA of -0.5626, highlighting the challenges faced by Day One.<BR><BR>The stock has underperformed against the S&P 500 across multiple time frames, with a year-to-date return of -43.09% compared to the S&P 500's 12.22%. This stark contrast reinforces the notion that Day One Biopharmaceuticals is currently overvalued in the market.

Is Day One Biopharmaceuticals, Inc. technically bullish or bearish?

As of September 26, 2025, Day One Biopharmaceuticals, Inc. has a mildly bearish trend, with mixed technical indicators and significant underperformance compared to the S&P 500, showing a year-to-date return of -46.57% versus the benchmark's 12.96%.

As of 26 September 2025, the technical trend for Day One Biopharmaceuticals, Inc. has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by a combination of indicators. The MACD shows a mildly bullish signal on the weekly chart but is bearish on the monthly, while the RSI indicates a bullish signal on the monthly but no signal on the weekly. Moving averages are bearish on the daily timeframe, and the KST and OBV are both mildly bearish on the weekly. <BR><BR>In terms of performance, the stock has underperformed significantly compared to the S&P 500, with a year-to-date return of -46.57% versus the benchmark's 12.96%, and a one-year return of -52.62% compared to 15.64% for the S&P 500.